GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
GYRE THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$6.09+0.01 (+0.16%)
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
GYRE THERAPEUTICS, INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Gyre Pharmaceuticals | $116.59M | $105.76M | $113.45M | – | – | – | 100.0% | +10.2% |
| BC | – | – | $113.45M | $102.29M | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | YoY |
|---|---|---|---|---|---|---|---|
| Gyre Pharmaceuticals | $19.99M | $22.02M | $24.46M | – | – | – | -9.2% |
| Other Unallocated Amount | -$19.00K | -$2.00K | -$3.29M | -$130.00K | – | – | +850.0% |
| Gyre | -$8.49M | -$5.86M | -$88.40M | – | – | – | +44.9% |
| BC | – | – | $24.46M | $9.33M | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| License | – | – | – | – | – | $15.10M | – | – |
| Collaboration | – | – | – | $794.00K | $7.34M | $5.85M | – | – |
| Exclusive License | – | – | – | – | – | $100.00K | – | – |
| License of Intellectual Property | – | – | – | $1.41M | – | – | – | – |
| ETUARY | – | $105.76M | $113.45M | $100.88M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Gyre Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.